Oxcarbazepine in bipolar disorder: a critical review of the literature

@article{Mazza2007OxcarbazepineIB,
  title={Oxcarbazepine in bipolar disorder: a critical review of the literature},
  author={Marianna Mazza and Marco Di Nicola and Giovanni Martinotti and Colombo Taranto and Gino Pozzi and Gian Luigi Conte and Luigi Janiri and Pietro Bria and Salvatore Mazza},
  journal={Expert Opinion on Pharmacotherapy},
  year={2007},
  volume={8},
  pages={649 - 656}
}
Oxcarbazepine (OXC) is a keto-congener of carbamazepine, which has fewer side effects and drug interactions. However, the efficacy of OXC in treating bipolar disorder is not as well established as that of carbamazepine. This article is a systematic literature review of all studies regarding OXC and bipolar disorders, with particular attention to papers published in the last 6 years. Using the terms ‘oxcarbazepine and bipolar disorder’, ‘oxcarbazepine and mania’ or ‘oxcarbazepine and bipolar… 

Oxcarbazepine for acute affective episodes in bipolar disorder.

There are insufficient trials of adequate methodological quality on oxcarbazepine in the acute treatment of bipolar disorder to inform us on its efficacy and acceptability.

Management of Bipolar Depression

The current status of available treatment strategies in the treatment of bipolar depression is summarized and results from clinical trials on psychosocial intervention are promising, especially when integrated with pharmacotherapy.

Late-onset hypersensitivity reaction with leukopenia and thrombocytopenia induced by oxcarbazepine treatment in a patient with schizoaffective disorder.

Those diagnosed with OCD by a mental health professional were significantly more likely to seek CBT treatment than those diagnosed by their primary care doctor or a nonprofessional, and there were no significant differences in gender, ethnicity, family income, or type of medical insurance between OCD sufferers who had soughtCBT treatment versus those who had not.

Oxcarbazepine as monotherapy of acute mania in insufficiently controlled type-1 diabetes mellitus: a case-report

OXC as monotherapy might be both safe and efficacious in the treatment of acute mania in patients with early-onset type-1 DM, whose already compromised physical condition constitutes an absolute or relative contra-indication for the administration of standard treatments, though there are no, as yet, randomized clinical trials attesting to its efficacy unambiguously.

A Practitioner’s Guide to Prescribing Oxcarbazepine for Adults with Intellectual Disabilities

The procedures contained in this guideline may not fully account for all of the possible risks of treatment in this population because of the limited studies available and there will be a need to periodically update this guideline as new information becomes available.

Gene expression and genetic association in bipolar disorder

The brain derived neurotrophic factor (BDNF) gene was found to be consistently upregulated across all six cell line/treatment combinations while the other genes showed inconsistent regulation.

Adverse event load in bipolar participants receiving either carbamazepine immediate-release or extended-release capsules: a blinded, randomized study

In epilepsy, slow-release formulations of carbamazepine (CBZ) have fewer adverse events (AEs) compared with immediate-release (IR) formulations. As CBZ is used for mania, it is important to determine

Late-Onset Hypersensitivity Reaction With Leukopenia and Thrombocytopenia Induced by Oxcarbazepine Treatment in a Patient With Schizoaffective Disorder

Those diagnosed with OCD by a mental health professional were significantly more likely to seek CBT treatment than those diagnosed by their primary care doctor or a nonprofessional (OR = 2.5, 95% CI = 1.3 to 5.0).

Clinical decision making in the treatment of mania.

  • R. Perlis
  • Psychology, Medicine
    The Journal of clinical psychiatry
  • 2008
Nine agents are now Food and Drug Administration-approved for acute treatment of bipolar mania, and several other agents are being studied for efficacy. With multiple treatment options available,

Epidemiology, Diagnosis and Management of Mixed Mania

The course and prognosis of mixed mania are worse than that of pure manic forms in the medium and long term, with higher recurrence rates, higher frequency of co-morbid substance abuse and greater risk of suicidal ideation and attempts.

References

SHOWING 1-10 OF 35 REFERENCES

Oxcarbazepine in the Treatment of Bipolar Disorder: A Review

The data indicate that OXC has efficacy inreating acute mania and may be a useful add-on in treating acute bipolar depression and in BD prophylaxis, and OxC is generally well-tolerated.

Efficacy and Safety of Oxcarbazepine in Bipolar Disorder

The usefulness of OXC monotherapy in severe mania appears doubtful because in the study by Hummel et al, the individual courses and scores of the Young Mania Rating Scale suggest a certain antimanic property of OxC only in patients with low-to-moderate manic episodes.

Oxcarbazepine add-on in the treatment of refractory bipolar disorder.

OXC was effective and well-tolerated in refractory BD and schizoaffective disorder and a significant reduction in symptoms as indicated by reduction in CGI-S scores at 1 and 2 months.

Oxcarbazepine treatment of bipolar disorder.

Oxcarbazepine appeared effective in about one half of patients with bipolar disorder and was well tolerated, and did not differentially predict response.

Anticonvulsants and antipsychotics in the treatment of bipolar disorder.

Preliminary data suggest that these agents may differ in their time course of antimanic activity and predictors of response, and may possess thymoleptic as well as antipsychotic activity, but they have not been studied in controlled trials in bipolar disorder.

Oxcarbazepine as add-on treatment in patients with bipolar manic, mixed or depressive episode.

Anticonvulsants in the treatment of bipolar mania

  • P. Goodnick
  • Psychology, Medicine
    Expert opinion on pharmacotherapy
  • 2006
A review of the kinetics, side effects and complications of the antiepileptic drugs indicates that carbamazepine is useful, and has adverse event benefit over all other options, and the potential of zonisamide awaits further testing.

Oxcarbazepine (Trileptal) in the treatment of bipolar disorders: a review of efficacy and tolerability.

  • J. Hellewell
  • Medicine, Psychology
    Journal of affective disorders
  • 2002

Oxcarbazepine: clinical experience with hospitalized psychiatric patients.

Oxcarbazepine was well tolerated and simpler to use clinically than its precursor carbamazepine, and should be studied in controlled trials to test its efficacy in specific types of major psychiatric disorders, and particularly for long-term maintenance treatment in bipolar disorder.

Acute antimanic efficacy and safety of oxcarbazepine in an open trial with an on-off-on design.

Antimanic activity of OXC was demonstrated in this pilot study only for patients with mild or moderate manic symptoms and whether it has a profile similar to that of carbamazepine is assessed.